Aytu BioPharma (AYTU) and Lupin's Lupin Pharma Canada unit said Tuesday that they have signed a collaborative, distribution and supply agreement for Aytu's two extended-release tablets for treating attention deficit hyperactivity disorder.
The agreement covers Adzenys XR-ODT and Cotempla XR-ODT product lines in Canada, according to the joint statement. Cotempla is a bioequivalent to Adderall XR.
Lupin said it will seek local regulatory and marketing authorizations for both drugs, which are already approved by the US Food and Drug Administration, in the next 18 to 24 months.
Price: 2.32, Change: -0.03, Percent Change: -1.32
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments